Prostatype Genomics Net Income vs. Market Capitalization

Please note, there is a significant difference between Prostatype Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Prostatype Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prostatype Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Prostatype Genomics Market Capitalization vs. Net Income Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Prostatype Genomics's current stock value. Our valuation model uses many indicators to compare Prostatype Genomics value to that of its competitors to determine the firm's financial worth.
Prostatype Genomics AB is considered to be number one stock in net income category among its peers. It is regarded second in market capitalization category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Prostatype Genomics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Prostatype Genomics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Prostatype Market Capitalization vs. Net Income

Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Prostatype Genomics

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(15.63 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.

Prostatype Genomics

Market Cap

 = 

Shares Outstanding

X

Share Price

 = 
42.29 M
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.

Prostatype Market Capitalization vs Competition

Prostatype Genomics AB is regarded second in market capitalization category among its peers. Market capitalization of Diagnostics & Research industry is at this time estimated at about 1.05 Billion. Prostatype Genomics holds roughly 42.29 Million in market capitalization claiming about 4% of equities under Diagnostics & Research industry.
Capitalization  Revenue  Total debt  Valuation  Workforce

Prostatype Genomics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Prostatype Genomics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Prostatype Genomics will eventually generate negative long term returns. The profitability progress is the general direction of Prostatype Genomics' change in net profit over the period of time. It can combine multiple indicators of Prostatype Genomics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. The company was founded in 2007 and is based in Solna, Sweden. Prostatype Genomics is traded on Stockholm Stock Exchange in Sweden.

Prostatype Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Prostatype Genomics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Prostatype Genomics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Prostatype Genomics' important profitability drivers and their relationship over time.

Prostatype Genomics Earnings per Share Projection vs Actual

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Prostatype Genomics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Valuation Now

   

Equity Valuation

Check real value of public entities based on technical and fundamental data
All  Next Launch Module

Use Investing Themes to Complement your Prostatype Genomics position

In addition to having Prostatype Genomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Diversified Assets Thematic Idea Now

Diversified Assets
Diversified Assets Theme
Pablicly traded close-end funds and other entities backed by different types of diversified investments. The Diversified Assets theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Diversified Assets Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Prostatype Stock

To fully project Prostatype Genomics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Prostatype Genomics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Prostatype Genomics' income statement, its balance sheet, and the statement of cash flows.
Potential Prostatype Genomics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Prostatype Genomics investors may work on each financial statement separately, they are all related. The changes in Prostatype Genomics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Prostatype Genomics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.